Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Dossier assessment
Adult patients with completely resected non-small cell lung cancer (NSCLC) at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-01-05 A G-BA decision was published.
Project details
- Project no.
- A22-67
- Commission
- Commission awarded on 05.07.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed